6 results on '"Feng,Weiwei"'
Search Results
2. The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.
3. Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.
4. Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.
5. Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.
6. Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.